TCR2

Recent Finacing

Series B

Recent Raise

$125M

TCR2 Therapeutics develops HLA-independent TCR-based cellular therapies using the TRuC platform to reprogram natural TCRs for persistent, low-cytokine cancer-cell killing in solid and blood tumors.